Literature DB >> 16151040

The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.

Svetlana Gelperina1, Kevin Kisich, Michael D Iseman, Leonid Heifets.   

Abstract

Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation. Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix. These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics. This article highlights some of the issues of nanotechnology relevant to the anti-TB drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16151040      PMCID: PMC2718451          DOI: 10.1164/rccm.200504-613PP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  29 in total

Review 1.  Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications.

Authors:  H Pinto-Alphandary; A Andremont; P Couvreur
Journal:  Int J Antimicrob Agents       Date:  2000-01       Impact factor: 5.283

2.  Liposome-encapsulated antibiotics.

Authors:  Isam I Salem; Diana L Flasher; Nejat Düzgüneş
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

Review 3.  Antitubercular inhaled therapy: opportunities, progress and challenges.

Authors:  Rajesh Pandey; G K Khuller
Journal:  J Antimicrob Chemother       Date:  2005-03-10       Impact factor: 5.790

Review 4.  PLGA nanoparticles in drug delivery: the state of the art.

Authors:  Indu Bala; Sarita Hariharan; M N V Ravi Kumar
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2004       Impact factor: 4.889

5.  Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.

Authors:  K Peters; S Leitzke; J E Diederichs; K Borner; H Hahn; R H Müller; S Ehlers
Journal:  J Antimicrob Chemother       Date:  2000-01       Impact factor: 5.790

6.  Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.

Authors:  Rajesh Pandey; G K Khuller
Journal:  Tuberculosis (Edinb)       Date:  2005-07       Impact factor: 3.131

7.  Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis.

Authors:  Anjali Sharma; Rajesh Pandey; Sadhna Sharma; G K Khuller
Journal:  Int J Antimicrob Agents       Date:  2004-12       Impact factor: 5.283

8.  Incorporation of polymeric nanoparticles into solid dosage forms.

Authors:  C Schmidt; R Bodmeier
Journal:  J Control Release       Date:  1999-02-01       Impact factor: 9.776

Review 9.  Solid lipid nanoparticles for parenteral drug delivery.

Authors:  S A Wissing; O Kayser; R H Müller
Journal:  Adv Drug Deliv Rev       Date:  2004-05-07       Impact factor: 15.470

10.  Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages.

Authors:  E L Barrow; G A Winchester; J K Staas; D C Quenelle; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more
  90 in total

Review 1.  Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis.

Authors:  Jonathan Paul Smith
Journal:  Yale J Biol Med       Date:  2011-12

2.  Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance.

Authors:  Rajendra S Kadam; David W A Bourne; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2012-04-12       Impact factor: 3.922

Review 3.  Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?

Authors:  Roudayna Diab; Chiraz Jaafar-Maalej; Hatem Fessi; Philippe Maincent
Journal:  AAPS J       Date:  2012-07-06       Impact factor: 4.009

4.  Synthesis and Characterization of L-Lysine Conjugated Silver Nanoparticles Smaller Than 10 nM.

Authors:  Jeremy Bonor; Vandhana Reddy; Hemanth Akkiraju; Prasad Dhurjati; Anja Nohe
Journal:  Adv Sci Eng Med       Date:  2014-09-01

Review 5.  Polymeric Nanostructures for Imaging and Therapy.

Authors:  Mahmoud Elsabahy; Gyu Seong Heo; Soon-Mi Lim; Guorong Sun; Karen L Wooley
Journal:  Chem Rev       Date:  2015-08-04       Impact factor: 60.622

6.  Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles.

Authors:  Chenchen Wang; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2010-03-26       Impact factor: 3.246

7.  Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.

Authors:  Faisal Usman; Jongdee Nopparat; Ibrahim Javed; Teerapol Srichana
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

Review 8.  Cure of tuberculosis using nanotechnology: An overview.

Authors:  Rout George Kerry; Sushanto Gouda; Bikram Sil; Gitishree Das; Han-Seung Shin; Gajanan Ghodake; Jayanta Kumar Patra
Journal:  J Microbiol       Date:  2018-05-02       Impact factor: 3.422

Review 9.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

Review 10.  Perspective on Nanoparticle Technology for Biomedical Use.

Authors:  Ramesh Raliya; Tandeep Singh Chadha; Kelsey Haddad; Pratim Biswas
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.